全文获取类型
收费全文 | 6111篇 |
免费 | 467篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 268篇 |
妇产科学 | 95篇 |
基础医学 | 805篇 |
口腔科学 | 78篇 |
临床医学 | 465篇 |
内科学 | 1319篇 |
皮肤病学 | 152篇 |
神经病学 | 314篇 |
特种医学 | 283篇 |
外科学 | 763篇 |
综合类 | 331篇 |
一般理论 | 6篇 |
预防医学 | 369篇 |
眼科学 | 127篇 |
药学 | 457篇 |
中国医学 | 33篇 |
肿瘤学 | 625篇 |
出版年
2023年 | 32篇 |
2022年 | 81篇 |
2021年 | 160篇 |
2020年 | 78篇 |
2019年 | 126篇 |
2018年 | 159篇 |
2017年 | 105篇 |
2016年 | 146篇 |
2015年 | 155篇 |
2014年 | 207篇 |
2013年 | 242篇 |
2012年 | 415篇 |
2011年 | 412篇 |
2010年 | 251篇 |
2009年 | 213篇 |
2008年 | 341篇 |
2007年 | 360篇 |
2006年 | 269篇 |
2005年 | 245篇 |
2004年 | 240篇 |
2003年 | 211篇 |
2002年 | 169篇 |
2001年 | 160篇 |
2000年 | 165篇 |
1999年 | 160篇 |
1998年 | 66篇 |
1997年 | 54篇 |
1996年 | 48篇 |
1995年 | 50篇 |
1994年 | 51篇 |
1993年 | 37篇 |
1992年 | 122篇 |
1991年 | 83篇 |
1990年 | 77篇 |
1989年 | 99篇 |
1988年 | 53篇 |
1987年 | 64篇 |
1986年 | 51篇 |
1985年 | 56篇 |
1984年 | 34篇 |
1983年 | 27篇 |
1982年 | 28篇 |
1979年 | 27篇 |
1977年 | 43篇 |
1976年 | 25篇 |
1974年 | 32篇 |
1973年 | 41篇 |
1972年 | 34篇 |
1971年 | 29篇 |
1967年 | 34篇 |
排序方式: 共有6597条查询结果,搜索用时 15 毫秒
101.
102.
A. S. Banerjee A. M. Shaaban D. Gibson M. G. Dilkes 《Indian journal of otolaryngology and head and neck surgery》2005,57(3):260-261
Self-inflicted laryngeal injuries are rare. This is a case of attempted suicide with a knife. The patient was brought into A&E and initial attempts at repair of the laryngo-skeletal structures were performed Later it became evident that the patient had an insensate hypofunctioning larynx. We present a technique aimed at rehabilitating the poorly functioning, incompetent larynx without the necessity for a permanent tracheostomy or laryngectomy. A single surgical procedure combining a cricopharyngeal myotomy, an anterior hyoid suspension and vocal fold angmentations was performed in an attempt to avoid a laryngectomy in non-malignant pathology. The long-term results of this surgery would need to be subjected to further evaluation. 相似文献
103.
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. 总被引:15,自引:0,他引:15
Activation of cell surface death receptors by their cognate ligands triggers apoptosis. Several human death receptors (Fas, TNF-R1, TRAMP, DR4, DR5, DR6, EDA-R and NGF-R) have been identified. The most promising cytokine for anticancer therapy is TRAIL/APO-2L, which induces apoptosis in cancer cells by binding to death receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. The cytotoxic activity of TRAIL is relatively selective to cancer cells compared to normal cells. Signaling by TRAIL and its receptors is tightly regulated process essential for key physiological functions in a variety of organs, as well as the maintenance of immune homeostasis. Despite early promising results, recent studies have identified several TRAIL-resistant cancer cells of various origins. Based on molecular analysis of death-receptor signaling pathways several new approaches have been developed to increase the efficacy of TRAIL. Resistance of cancer cells to TRAIL appears to occur through the modulation of various molecular targets. They may include differential expression of death receptors, constitutively active Akt and NFkappaB, overexpression of cFLIP and IAPs, mutations in Bax and Bak genes, and defects in the release of mitochondrial proteins in resistant cells. Conventional chemotherapeutic and chemopreventive drugs, and irradiation can sensitize TRAIL-resistant cells to undergo apoptosis. Thus, these agents enhance the therapeutic potential of TRAIL in TRAIL-sensitive cells and sensitize TRAIL-resistant cells. TRAIL and TRAIL-receptor antibodies may prove to be useful for cancer therapy, either alone or in association with conventional approaches such as chemotherapy or radiation therapy. This review discusses intracellular mechanisms of TRAIL resistance and various approaches that can be taken to sensitize TRAIL-resistant cancer cells. 相似文献
104.
105.
There is mounting evidence that combination of antibiotic therapy with vancomycin and piperacillin/tazobactam (pip/tazo) is associated with acute kidney injury (AKI). To determine whether vancomycin plus pip/tazo is associated with higher rates of AKI compared to vancomycin plus cefepime among pediatric hematology/oncology (heme/onc) patients, we examined 121 heme/onc patients receiving at least two consecutive days of therapy with vancomycin and either pip/tazo or cefepime. Rate of AKI was higher in the pip/tazo than the cefepime group (4/27 [14.8%] vs 2/94 [2.1%], P = 0.022). 相似文献
106.
107.
108.
109.
110.